Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T15:36:04.940Z.
Calculation as of: 2026-10-06T15:36:04.940Z.
Quote observation: 2026-10-06T15:35:03.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0793561984d12013d5f07d0ccc5da74adc08ebcd6005adbeade30d207b80f537
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Cognition Therapeutics, Inc.
Market Cap
$85.01M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$85.01M
EV/EBITDA Ratio
N/A
TTM Avg
8.06x
3Y Avg
8.06x
5Y Avg
8.06x
Market Cap
$85.01M
EV/EBITDA Ratio
N/A
TTM Avg
12.88x
3Y Avg
47.67x
5Y Avg
47.67x
Market Cap
$83.04M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cognition Therapeutics, Inc. (CGTX) | $85.01M | N/A | N/A | N/A | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $85.01M | N/A | 8.06x | 8.06x | 8.06x |
| Humacyte, Inc. (HUMA)vs › | $85.16M | N/A | N/A | N/A | N/A |
| ProMIS Neurosciences, Inc. (PMN)vs › | $85.01M | N/A | 12.88x | 47.67x | 47.67x |
| Cardiff Oncology, Inc. (CRDF)vs › | $85.17M | N/A | N/A | N/A | N/A |
| Nutriband Inc. (NTRB)vs › | $81.57M | N/A | N/A | N/A | N/A |
| MediciNova, Inc. (MNOV)vs › | $83.18M | N/A | N/A | N/A | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $83.04M | N/A | N/A | N/A | N/A |
| CareCloud, Inc. (CCLD)vs › | $86.90M | 4.64x | 4.46x | 3.36x | 3.41x |
| LENSAR Inc (LNSR)vs › | $82.41M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
